Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 Visualizzazioni
• 07/18/23
0
0
Incorporare
administrator
Iscritti
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti